Hyperhomocysteinemia Confers an Independent Increased Risk of Atherosclerosis in End-Stage Renal Disease and Is Closely Linked to Plasma Folate and Pyridoxine Concentrations
- 1 December 1996
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Cell Metabolism
- Vol. 94 (11), 2743-2748
- https://doi.org/10.1161/01.cir.94.11.2743
Abstract
Background A high level of total plasma homocysteine is a risk factor for atherosclerosis, which is an important cause of death in renal failure. We evaluated the role of this as a risk factor for vascular complications of end-stage renal disease. Methods and Results Total fasting plasma homocysteine and other risk factors were documented in 176 dialysis patients (97 men, 79 women; mean age, 56.3±14.8 years). Folate, vitamin B 12 , and pyridoxal phosphate concentrations were also determined. The prevalence of high total homocysteine values was determined by comparison with a normal reference population, and the risk of associated vascular complications was estimated by multiple logistic regression. Total homocysteine concentration was higher in patients than in the normal population (26.6±1.5 versus 10.1±1.7 μmol/L; P <.01). Abnormally high concentrations (>95th percentile for control subjects, 16.3 μmol/L) were seen in 149 patients (85%) with end-stage renal disease ( P <.001). Patients with a homocysteine concentration in the upper two quintiles (>27.8 μmol/L) had an independent odds ratio of 2.9 (CI, 1.4 to 5.8; P =.007) of vascular complications. B vitamin levels were lower in patients with vascular complications than in those without. Vitamin B 6 deficiency was more frequent in patients than in the normal reference population (18% versus 2%; P <.01). Conclusions A high total plasma homocysteine concentration is an independent risk factor for atherosclerotic complications of end-stage renal disease. Such patients may benefit from higher doses of B vitamins than those currently recommended.Keywords
This publication has 37 references indexed in Scilit:
- Homocysteine and coronary atherosclerosisJournal of the American College of Cardiology, 1996
- High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patientsKidney International, 1996
- Hyperhomocysteinaemia: a role in the accelerated atherogenesis of chronic renal failure?The Netherlands Journal of Medicine, 1995
- Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control studyAtherosclerosis, 1995
- Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patientsThe American Journal of Cardiology, 1995
- Hyperhomocysteinemia: An Independent Risk Factor for Vascular DiseaseNew England Journal of Medicine, 1991
- Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptorBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1987
- Heterozygosity for Homocystinuria in Premature Peripheral and Cerebral Occlusive Arterial DiseaseNew England Journal of Medicine, 1985
- Daily requirement for pyridoxine supplements in chronic renal failureKidney International, 1981
- Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine‐homocysteine mixed disulphideEuropean Journal of Clinical Investigation, 1979